|
Selumetinib Clinical Trials
4 actively recruiting trials across 3 locations
▲ +1 trial since July 2026
Also known as: AZD6244, Koselugo, koselugo
Pipeline
Phase 1: 1Phase 2: 1Phase 1/2: 2
Top Sponsors
- University of Chicago1
- University of Alabama at Birmingham1
- Gustave Roussy, Cancer Campus, Grand Paris1
- AeRang Kim1
Indications
- Cancer4
- Neurofibromatosis 1 (NF1)1
- Atypical Neurofibroma1
- Myelofibroses1
- Malignant Peripheral Nerve Sheath Tumor (MPNST)1
Other1 trial
Birmingham, Alabama1 trial
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Childrens of Alabama
Phase 2
Washington D.C., District of Columbia1 trial
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Children's National Hospital
Phase 1/2
Chicago, Illinois1 trial
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
The University of Chicago
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.